カテゴリー： 世界, 医療/バイオ, LP Information

世界の成人非ホジキンリンパ腫治療市場予測 2023年-2029年

【英語タイトル】Global Adult Non-Hodgkin Lymphoma Treatment Market Growth 2023-2029

LP Informationが出版した調査資料（LP23DC02391）・商品コード：LP23DC02391
・発行会社（調査会社）：LP Information
・発行日：2023年11月
・ページ数：106
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥556,320見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥834,480見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,112,640見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界の成人非ホジキンリンパ腫治療市場」は、過去の販売実績から2022年の世界の成人非ホジキンリンパ腫治療の総販売量を検討し、2023年から2029年の予測される成人非ホジキンリンパ腫治療の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の成人非ホジキンリンパ腫治療の市場規模を掲載し、XXX百万米ドル規模の世界の成人非ホジキンリンパ腫治療市場の詳細な分析を提供します。本インサイトレポートは、世界の成人非ホジキンリンパ腫治療業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の成人非ホジキンリンパ腫治療市場における各社の独自のポジションをより深く理解するために、成人非ホジキンリンパ腫治療製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の成人非ホジキンリンパ腫治療市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。成人非ホジキンリンパ腫治療の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。成人非ホジキンリンパ腫治療の中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。成人非ホジキンリンパ腫治療のヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

成人非ホジキンリンパ腫治療の世界主要メーカーとしては、Janssen Pharma、 Genentech, Inc.、 CELGENE CORPORATION、 Merck & Co.,Inc.、 Kyowa Kirin Co., Ltd.、 AbbVie Inc.、 Sanofi、 Takeda Pharmaceutical Company、 AstraZeneca、 Bayer AGNovartis AG、 Kite Pharma, Inc、 Spectrum Pharmaceuticals, Inc.、 Teva Pharmaceutical lndustries Ltd.、 Bristol Myers Squibb Companyなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の成人非ホジキンリンパ腫治療市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査では成人非ホジキンリンパ腫治療市場をセグメンテーションし、種類別 (B細胞、T細胞、NK/T細胞)、用途別 (病院、クリニック)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：B細胞、T細胞、NK/T細胞

・用途別区分：病院、クリニック

・地域別区分
南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界の成人非ホジキンリンパ腫治療市場の10年間の市場状況・展望は？
・世界および地域別に見た成人非ホジキンリンパ腫治療市場成長の要因は何か？
・成人非ホジキンリンパ腫治療の市場機会はエンドマーケットの規模によってどのように変化するのか？
・成人非ホジキンリンパ腫治療のタイプ別、用途別の内訳は？
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：成人非ホジキンリンパ腫治療の年間販売量2018-2029、地域別現状・将来分析
・成人非ホジキンリンパ腫治療の種類別セグメント：B細胞、T細胞、NK/T細胞
・成人非ホジキンリンパ腫治療の種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・成人非ホジキンリンパ腫治療の用途別セグメント：病院、クリニック
・成人非ホジキンリンパ腫治療の用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の成人非ホジキンリンパ腫治療市場
・企業別のグローバル成人非ホジキンリンパ腫治療市場データ：2018-2023年の年間販売量、市場シェア
・企業別の成人非ホジキンリンパ腫治療の年間売上：2018-2023年の売上、市場シェア
・企業別の成人非ホジキンリンパ腫治療販売価格
・主要企業の成人非ホジキンリンパ腫治療生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

成人非ホジキンリンパ腫治療の地域別レビュー
・地域別の成人非ホジキンリンパ腫治療市場規模2018-2023：年間販売量、売上
・主要国別の成人非ホジキンリンパ腫治療市場規模2018-2023：年間販売量、売上
・南北アメリカの成人非ホジキンリンパ腫治療販売の成長
・アジア太平洋の成人非ホジキンリンパ腫治療販売の成長
・ヨーロッパの成人非ホジキンリンパ腫治療販売の成長
・中東・アフリカの成人非ホジキンリンパ腫治療販売の成長

南北アメリカ市場
・南北アメリカの国別の成人非ホジキンリンパ腫治療販売量、売上（2018-2023）
・南北アメリカの成人非ホジキンリンパ腫治療の種類別販売量
・南北アメリカの成人非ホジキンリンパ腫治療の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の成人非ホジキンリンパ腫治療販売量、売上（2018-2023）
・アジア太平洋の成人非ホジキンリンパ腫治療の種類別販売量
・アジア太平洋の成人非ホジキンリンパ腫治療の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の成人非ホジキンリンパ腫治療販売量、売上（2018-2023）
・ヨーロッパの成人非ホジキンリンパ腫治療の種類別販売量
・ヨーロッパの成人非ホジキンリンパ腫治療の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の成人非ホジキンリンパ腫治療販売量、売上（2018-2023）
・中東・アフリカの成人非ホジキンリンパ腫治療の種類別販売量
・中東・アフリカの成人非ホジキンリンパ腫治療の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・成人非ホジキンリンパ腫治療の製造コスト構造分析
・成人非ホジキンリンパ腫治療の製造プロセス分析
・成人非ホジキンリンパ腫治療の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・成人非ホジキンリンパ腫治療の主要なグローバル販売業者
・成人非ホジキンリンパ腫治療の主要なグローバル顧客

地域別の成人非ホジキンリンパ腫治療市場予測レビュー
・地域別の成人非ホジキンリンパ腫治療市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・成人非ホジキンリンパ腫治療の種類別市場規模予測
・成人非ホジキンリンパ腫治療の用途別市場規模予測

主要企業分析
Janssen Pharma、 Genentech, Inc.、 CELGENE CORPORATION、 Merck & Co.,Inc.、 Kyowa Kirin Co., Ltd.、 AbbVie Inc.、 Sanofi、 Takeda Pharmaceutical Company、 AstraZeneca、 Bayer AGNovartis AG、 Kite Pharma, Inc、 Spectrum Pharmaceuticals, Inc.、 Teva Pharmaceutical lndustries Ltd.、 Bristol Myers Squibb Company
・企業情報
・成人非ホジキンリンパ腫治療製品
・成人非ホジキンリンパ腫治療販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

The global Adult Non-Hodgkin Lymphoma Treatment market size is projected to grow from US$ 7434.7 million in 2022 to US$ 13340 million in 2029; it is expected to grow at a CAGR of 8.7% from 2023 to 2029.
United States market for Adult Non-Hodgkin Lymphoma Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Adult Non-Hodgkin Lymphoma Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Adult Non-Hodgkin Lymphoma Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Adult Non-Hodgkin Lymphoma Treatment players cover Janssen Pharma, Genentech, Inc., CELGENE CORPORATION, Merck & Co.,Inc., Kyowa Kirin Co., Ltd., AbbVie Inc., Sanofi, Takeda Pharmaceutical Company and AstraZeneca, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Non-Hodgkin lymphoma (NHL) is an umbrella term for a group of independent diseases with strong heterogeneity
LPI (LP Information)’ newest research report, the “Adult Non-Hodgkin Lymphoma Treatment Industry Forecast” looks at past sales and reviews total world Adult Non-Hodgkin Lymphoma Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Adult Non-Hodgkin Lymphoma Treatment sales for 2023 through 2029. With Adult Non-Hodgkin Lymphoma Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Adult Non-Hodgkin Lymphoma Treatment industry.
This Insight Report provides a comprehensive analysis of the global Adult Non-Hodgkin Lymphoma Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Adult Non-Hodgkin Lymphoma Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Adult Non-Hodgkin Lymphoma Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Adult Non-Hodgkin Lymphoma Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Adult Non-Hodgkin Lymphoma Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Adult Non-Hodgkin Lymphoma Treatment market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
B Cell
T Cell
NK/T Cells
Segmentation by application
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Janssen Pharma
Genentech, Inc.
CELGENE CORPORATION
Merck & Co.,Inc.
Kyowa Kirin Co., Ltd.
AbbVie Inc.
Sanofi
Takeda Pharmaceutical Company
AstraZeneca
Bayer AGNovartis AG
Kite Pharma, Inc
Spectrum Pharmaceuticals, Inc.
Teva Pharmaceutical lndustries Ltd.
Bristol Myers Squibb Company
Key Questions Addressed in this Report
What is the 10-year outlook for the global Adult Non-Hodgkin Lymphoma Treatment market?
What factors are driving Adult Non-Hodgkin Lymphoma Treatment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Adult Non-Hodgkin Lymphoma Treatment market opportunities vary by end market size?
How does Adult Non-Hodgkin Lymphoma Treatment break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Adult Non-Hodgkin Lymphoma Treatment Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Adult Non-Hodgkin Lymphoma Treatment by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Adult Non-Hodgkin Lymphoma Treatment by Country/Region, 2018, 2022 & 2029
2.2 Adult Non-Hodgkin Lymphoma Treatment Segment by Type
2.2.1 B Cell
2.2.2 T Cell
2.2.3 NK/T Cells
2.3 Adult Non-Hodgkin Lymphoma Treatment Sales by Type
2.3.1 Global Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Type (2018-2023)
2.3.2 Global Adult Non-Hodgkin Lymphoma Treatment Revenue and Market Share by Type (2018-2023)
2.3.3 Global Adult Non-Hodgkin Lymphoma Treatment Sale Price by Type (2018-2023)
2.4 Adult Non-Hodgkin Lymphoma Treatment Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Adult Non-Hodgkin Lymphoma Treatment Sales by Application
2.5.1 Global Adult Non-Hodgkin Lymphoma Treatment Sale Market Share by Application (2018-2023)
2.5.2 Global Adult Non-Hodgkin Lymphoma Treatment Revenue and Market Share by Application (2018-2023)
2.5.3 Global Adult Non-Hodgkin Lymphoma Treatment Sale Price by Application (2018-2023)
3 Global Adult Non-Hodgkin Lymphoma Treatment by Company
3.1 Global Adult Non-Hodgkin Lymphoma Treatment Breakdown Data by Company
3.1.1 Global Adult Non-Hodgkin Lymphoma Treatment Annual Sales by Company (2018-2023)
3.1.2 Global Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Company (2018-2023)
3.2 Global Adult Non-Hodgkin Lymphoma Treatment Annual Revenue by Company (2018-2023)
3.2.1 Global Adult Non-Hodgkin Lymphoma Treatment Revenue by Company (2018-2023)
3.2.2 Global Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Company (2018-2023)
3.3 Global Adult Non-Hodgkin Lymphoma Treatment Sale Price by Company
3.4 Key Manufacturers Adult Non-Hodgkin Lymphoma Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Adult Non-Hodgkin Lymphoma Treatment Product Location Distribution
3.4.2 Players Adult Non-Hodgkin Lymphoma Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Adult Non-Hodgkin Lymphoma Treatment by Geographic Region
4.1 World Historic Adult Non-Hodgkin Lymphoma Treatment Market Size by Geographic Region (2018-2023)
4.1.1 Global Adult Non-Hodgkin Lymphoma Treatment Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Adult Non-Hodgkin Lymphoma Treatment Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Adult Non-Hodgkin Lymphoma Treatment Market Size by Country/Region (2018-2023)
4.2.1 Global Adult Non-Hodgkin Lymphoma Treatment Annual Sales by Country/Region (2018-2023)
4.2.2 Global Adult Non-Hodgkin Lymphoma Treatment Annual Revenue by Country/Region (2018-2023)
4.3 Americas Adult Non-Hodgkin Lymphoma Treatment Sales Growth
4.4 APAC Adult Non-Hodgkin Lymphoma Treatment Sales Growth
4.5 Europe Adult Non-Hodgkin Lymphoma Treatment Sales Growth
4.6 Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Sales Growth
5 Americas
5.1 Americas Adult Non-Hodgkin Lymphoma Treatment Sales by Country
5.1.1 Americas Adult Non-Hodgkin Lymphoma Treatment Sales by Country (2018-2023)
5.1.2 Americas Adult Non-Hodgkin Lymphoma Treatment Revenue by Country (2018-2023)
5.2 Americas Adult Non-Hodgkin Lymphoma Treatment Sales by Type
5.3 Americas Adult Non-Hodgkin Lymphoma Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Adult Non-Hodgkin Lymphoma Treatment Sales by Region
6.1.1 APAC Adult Non-Hodgkin Lymphoma Treatment Sales by Region (2018-2023)
6.1.2 APAC Adult Non-Hodgkin Lymphoma Treatment Revenue by Region (2018-2023)
6.2 APAC Adult Non-Hodgkin Lymphoma Treatment Sales by Type
6.3 APAC Adult Non-Hodgkin Lymphoma Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Adult Non-Hodgkin Lymphoma Treatment by Country
7.1.1 Europe Adult Non-Hodgkin Lymphoma Treatment Sales by Country (2018-2023)
7.1.2 Europe Adult Non-Hodgkin Lymphoma Treatment Revenue by Country (2018-2023)
7.2 Europe Adult Non-Hodgkin Lymphoma Treatment Sales by Type
7.3 Europe Adult Non-Hodgkin Lymphoma Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment by Country
8.1.1 Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Sales by Country (2018-2023)
8.1.2 Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Revenue by Country (2018-2023)
8.2 Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Sales by Type
8.3 Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Adult Non-Hodgkin Lymphoma Treatment
10.3 Manufacturing Process Analysis of Adult Non-Hodgkin Lymphoma Treatment
10.4 Industry Chain Structure of Adult Non-Hodgkin Lymphoma Treatment
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Adult Non-Hodgkin Lymphoma Treatment Distributors
11.3 Adult Non-Hodgkin Lymphoma Treatment Customer
12 World Forecast Review for Adult Non-Hodgkin Lymphoma Treatment by Geographic Region
12.1 Global Adult Non-Hodgkin Lymphoma Treatment Market Size Forecast by Region
12.1.1 Global Adult Non-Hodgkin Lymphoma Treatment Forecast by Region (2024-2029)
12.1.2 Global Adult Non-Hodgkin Lymphoma Treatment Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Adult Non-Hodgkin Lymphoma Treatment Forecast by Type
12.7 Global Adult Non-Hodgkin Lymphoma Treatment Forecast by Application
13 Key Players Analysis
13.1 Janssen Pharma
13.1.1 Janssen Pharma Company Information
13.1.2 Janssen Pharma Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
13.1.3 Janssen Pharma Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Janssen Pharma Main Business Overview
13.1.5 Janssen Pharma Latest Developments
13.2 Genentech, Inc.
13.2.1 Genentech, Inc. Company Information
13.2.2 Genentech, Inc. Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
13.2.3 Genentech, Inc. Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Genentech, Inc. Main Business Overview
13.2.5 Genentech, Inc. Latest Developments
13.3 CELGENE CORPORATION
13.3.1 CELGENE CORPORATION Company Information
13.3.2 CELGENE CORPORATION Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
13.3.3 CELGENE CORPORATION Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 CELGENE CORPORATION Main Business Overview
13.3.5 CELGENE CORPORATION Latest Developments
13.4 Merck & Co.,Inc.
13.4.1 Merck & Co.,Inc. Company Information
13.4.2 Merck & Co.,Inc. Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
13.4.3 Merck & Co.,Inc. Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Merck & Co.,Inc. Main Business Overview
13.4.5 Merck & Co.,Inc. Latest Developments
13.5 Kyowa Kirin Co., Ltd.
13.5.1 Kyowa Kirin Co., Ltd. Company Information
13.5.2 Kyowa Kirin Co., Ltd. Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
13.5.3 Kyowa Kirin Co., Ltd. Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Kyowa Kirin Co., Ltd. Main Business Overview
13.5.5 Kyowa Kirin Co., Ltd. Latest Developments
13.6 AbbVie Inc.
13.6.1 AbbVie Inc. Company Information
13.6.2 AbbVie Inc. Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
13.6.3 AbbVie Inc. Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 AbbVie Inc. Main Business Overview
13.6.5 AbbVie Inc. Latest Developments
13.7 Sanofi
13.7.1 Sanofi Company Information
13.7.2 Sanofi Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
13.7.3 Sanofi Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Sanofi Main Business Overview
13.7.5 Sanofi Latest Developments
13.8 Takeda Pharmaceutical Company
13.8.1 Takeda Pharmaceutical Company Company Information
13.8.2 Takeda Pharmaceutical Company Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
13.8.3 Takeda Pharmaceutical Company Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Takeda Pharmaceutical Company Main Business Overview
13.8.5 Takeda Pharmaceutical Company Latest Developments
13.9 AstraZeneca
13.9.1 AstraZeneca Company Information
13.9.2 AstraZeneca Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
13.9.3 AstraZeneca Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 AstraZeneca Main Business Overview
13.9.5 AstraZeneca Latest Developments
13.10 Bayer AGNovartis AG
13.10.1 Bayer AGNovartis AG Company Information
13.10.2 Bayer AGNovartis AG Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
13.10.3 Bayer AGNovartis AG Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Bayer AGNovartis AG Main Business Overview
13.10.5 Bayer AGNovartis AG Latest Developments
13.11 Kite Pharma, Inc
13.11.1 Kite Pharma, Inc Company Information
13.11.2 Kite Pharma, Inc Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
13.11.3 Kite Pharma, Inc Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Kite Pharma, Inc Main Business Overview
13.11.5 Kite Pharma, Inc Latest Developments
13.12 Spectrum Pharmaceuticals, Inc.
13.12.1 Spectrum Pharmaceuticals, Inc. Company Information
13.12.2 Spectrum Pharmaceuticals, Inc. Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
13.12.3 Spectrum Pharmaceuticals, Inc. Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Spectrum Pharmaceuticals, Inc. Main Business Overview
13.12.5 Spectrum Pharmaceuticals, Inc. Latest Developments
13.13 Teva Pharmaceutical lndustries Ltd.
13.13.1 Teva Pharmaceutical lndustries Ltd. Company Information
13.13.2 Teva Pharmaceutical lndustries Ltd. Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
13.13.3 Teva Pharmaceutical lndustries Ltd. Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Teva Pharmaceutical lndustries Ltd. Main Business Overview
13.13.5 Teva Pharmaceutical lndustries Ltd. Latest Developments
13.14 Bristol Myers Squibb Company
13.14.1 Bristol Myers Squibb Company Company Information
13.14.2 Bristol Myers Squibb Company Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
13.14.3 Bristol Myers Squibb Company Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Bristol Myers Squibb Company Main Business Overview
13.14.5 Bristol Myers Squibb Company Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Adult Non-Hodgkin Lymphoma Treatment Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Adult Non-Hodgkin Lymphoma Treatment Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of B Cell
Table 4. Major Players of T Cell
Table 5. Major Players of NK/T Cells
Table 6. Global Adult Non-Hodgkin Lymphoma Treatment Sales by Type (2018-2023) & (K Units)
Table 7. Global Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Type (2018-2023)
Table 8. Global Adult Non-Hodgkin Lymphoma Treatment Revenue by Type (2018-2023) & ($ million)
Table 9. Global Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2018-2023)
Table 10. Global Adult Non-Hodgkin Lymphoma Treatment Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global Adult Non-Hodgkin Lymphoma Treatment Sales by Application (2018-2023) & (K Units)
Table 12. Global Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Application (2018-2023)
Table 13. Global Adult Non-Hodgkin Lymphoma Treatment Revenue by Application (2018-2023)
Table 14. Global Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Application (2018-2023)
Table 15. Global Adult Non-Hodgkin Lymphoma Treatment Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global Adult Non-Hodgkin Lymphoma Treatment Sales by Company (2018-2023) & (K Units)
Table 17. Global Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Company (2018-2023)
Table 18. Global Adult Non-Hodgkin Lymphoma Treatment Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Company (2018-2023)
Table 20. Global Adult Non-Hodgkin Lymphoma Treatment Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers Adult Non-Hodgkin Lymphoma Treatment Producing Area Distribution and Sales Area
Table 22. Players Adult Non-Hodgkin Lymphoma Treatment Products Offered
Table 23. Adult Non-Hodgkin Lymphoma Treatment Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Adult Non-Hodgkin Lymphoma Treatment Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Adult Non-Hodgkin Lymphoma Treatment Sales Market Share Geographic Region (2018-2023)
Table 28. Global Adult Non-Hodgkin Lymphoma Treatment Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Adult Non-Hodgkin Lymphoma Treatment Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Country/Region (2018-2023)
Table 32. Global Adult Non-Hodgkin Lymphoma Treatment Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Adult Non-Hodgkin Lymphoma Treatment Sales by Country (2018-2023) & (K Units)
Table 35. Americas Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Country (2018-2023)
Table 36. Americas Adult Non-Hodgkin Lymphoma Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Country (2018-2023)
Table 38. Americas Adult Non-Hodgkin Lymphoma Treatment Sales by Type (2018-2023) & (K Units)
Table 39. Americas Adult Non-Hodgkin Lymphoma Treatment Sales by Application (2018-2023) & (K Units)
Table 40. APAC Adult Non-Hodgkin Lymphoma Treatment Sales by Region (2018-2023) & (K Units)
Table 41. APAC Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Region (2018-2023)
Table 42. APAC Adult Non-Hodgkin Lymphoma Treatment Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Region (2018-2023)
Table 44. APAC Adult Non-Hodgkin Lymphoma Treatment Sales by Type (2018-2023) & (K Units)
Table 45. APAC Adult Non-Hodgkin Lymphoma Treatment Sales by Application (2018-2023) & (K Units)
Table 46. Europe Adult Non-Hodgkin Lymphoma Treatment Sales by Country (2018-2023) & (K Units)
Table 47. Europe Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Country (2018-2023)
Table 48. Europe Adult Non-Hodgkin Lymphoma Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Country (2018-2023)
Table 50. Europe Adult Non-Hodgkin Lymphoma Treatment Sales by Type (2018-2023) & (K Units)
Table 51. Europe Adult Non-Hodgkin Lymphoma Treatment Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Adult Non-Hodgkin Lymphoma Treatment
Table 59. Key Market Challenges & Risks of Adult Non-Hodgkin Lymphoma Treatment
Table 60. Key Industry Trends of Adult Non-Hodgkin Lymphoma Treatment
Table 61. Adult Non-Hodgkin Lymphoma Treatment Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Adult Non-Hodgkin Lymphoma Treatment Distributors List
Table 64. Adult Non-Hodgkin Lymphoma Treatment Customer List
Table 65. Global Adult Non-Hodgkin Lymphoma Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Adult Non-Hodgkin Lymphoma Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Adult Non-Hodgkin Lymphoma Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Adult Non-Hodgkin Lymphoma Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Adult Non-Hodgkin Lymphoma Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Adult Non-Hodgkin Lymphoma Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Adult Non-Hodgkin Lymphoma Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Adult Non-Hodgkin Lymphoma Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Adult Non-Hodgkin Lymphoma Treatment Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Adult Non-Hodgkin Lymphoma Treatment Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Adult Non-Hodgkin Lymphoma Treatment Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Adult Non-Hodgkin Lymphoma Treatment Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Janssen Pharma Basic Information, Adult Non-Hodgkin Lymphoma Treatment Manufacturing Base, Sales Area and Its Competitors
Table 80. Janssen Pharma Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
Table 81. Janssen Pharma Adult Non-Hodgkin Lymphoma Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. Janssen Pharma Main Business
Table 83. Janssen Pharma Latest Developments
Table 84. Genentech, Inc. Basic Information, Adult Non-Hodgkin Lymphoma Treatment Manufacturing Base, Sales Area and Its Competitors
Table 85. Genentech, Inc. Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
Table 86. Genentech, Inc. Adult Non-Hodgkin Lymphoma Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. Genentech, Inc. Main Business
Table 88. Genentech, Inc. Latest Developments
Table 89. CELGENE CORPORATION Basic Information, Adult Non-Hodgkin Lymphoma Treatment Manufacturing Base, Sales Area and Its Competitors
Table 90. CELGENE CORPORATION Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
Table 91. CELGENE CORPORATION Adult Non-Hodgkin Lymphoma Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. CELGENE CORPORATION Main Business
Table 93. CELGENE CORPORATION Latest Developments
Table 94. Merck & Co.,Inc. Basic Information, Adult Non-Hodgkin Lymphoma Treatment Manufacturing Base, Sales Area and Its Competitors
Table 95. Merck & Co.,Inc. Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
Table 96. Merck & Co.,Inc. Adult Non-Hodgkin Lymphoma Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Merck & Co.,Inc. Main Business
Table 98. Merck & Co.,Inc. Latest Developments
Table 99. Kyowa Kirin Co., Ltd. Basic Information, Adult Non-Hodgkin Lymphoma Treatment Manufacturing Base, Sales Area and Its Competitors
Table 100. Kyowa Kirin Co., Ltd. Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
Table 101. Kyowa Kirin Co., Ltd. Adult Non-Hodgkin Lymphoma Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Kyowa Kirin Co., Ltd. Main Business
Table 103. Kyowa Kirin Co., Ltd. Latest Developments
Table 104. AbbVie Inc. Basic Information, Adult Non-Hodgkin Lymphoma Treatment Manufacturing Base, Sales Area and Its Competitors
Table 105. AbbVie Inc. Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
Table 106. AbbVie Inc. Adult Non-Hodgkin Lymphoma Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. AbbVie Inc. Main Business
Table 108. AbbVie Inc. Latest Developments
Table 109. Sanofi Basic Information, Adult Non-Hodgkin Lymphoma Treatment Manufacturing Base, Sales Area and Its Competitors
Table 110. Sanofi Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
Table 111. Sanofi Adult Non-Hodgkin Lymphoma Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Sanofi Main Business
Table 113. Sanofi Latest Developments
Table 114. Takeda Pharmaceutical Company Basic Information, Adult Non-Hodgkin Lymphoma Treatment Manufacturing Base, Sales Area and Its Competitors
Table 115. Takeda Pharmaceutical Company Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
Table 116. Takeda Pharmaceutical Company Adult Non-Hodgkin Lymphoma Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. Takeda Pharmaceutical Company Main Business
Table 118. Takeda Pharmaceutical Company Latest Developments
Table 119. AstraZeneca Basic Information, Adult Non-Hodgkin Lymphoma Treatment Manufacturing Base, Sales Area and Its Competitors
Table 120. AstraZeneca Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
Table 121. AstraZeneca Adult Non-Hodgkin Lymphoma Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. AstraZeneca Main Business
Table 123. AstraZeneca Latest Developments
Table 124. Bayer AGNovartis AG Basic Information, Adult Non-Hodgkin Lymphoma Treatment Manufacturing Base, Sales Area and Its Competitors
Table 125. Bayer AGNovartis AG Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
Table 126. Bayer AGNovartis AG Adult Non-Hodgkin Lymphoma Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. Bayer AGNovartis AG Main Business
Table 128. Bayer AGNovartis AG Latest Developments
Table 129. Kite Pharma, Inc Basic Information, Adult Non-Hodgkin Lymphoma Treatment Manufacturing Base, Sales Area and Its Competitors
Table 130. Kite Pharma, Inc Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
Table 131. Kite Pharma, Inc Adult Non-Hodgkin Lymphoma Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 132. Kite Pharma, Inc Main Business
Table 133. Kite Pharma, Inc Latest Developments
Table 134. Spectrum Pharmaceuticals, Inc. Basic Information, Adult Non-Hodgkin Lymphoma Treatment Manufacturing Base, Sales Area and Its Competitors
Table 135. Spectrum Pharmaceuticals, Inc. Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
Table 136. Spectrum Pharmaceuticals, Inc. Adult Non-Hodgkin Lymphoma Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 137. Spectrum Pharmaceuticals, Inc. Main Business
Table 138. Spectrum Pharmaceuticals, Inc. Latest Developments
Table 139. Teva Pharmaceutical lndustries Ltd. Basic Information, Adult Non-Hodgkin Lymphoma Treatment Manufacturing Base, Sales Area and Its Competitors
Table 140. Teva Pharmaceutical lndustries Ltd. Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
Table 141. Teva Pharmaceutical lndustries Ltd. Adult Non-Hodgkin Lymphoma Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 142. Teva Pharmaceutical lndustries Ltd. Main Business
Table 143. Teva Pharmaceutical lndustries Ltd. Latest Developments
Table 144. Bristol Myers Squibb Company Basic Information, Adult Non-Hodgkin Lymphoma Treatment Manufacturing Base, Sales Area and Its Competitors
Table 145. Bristol Myers Squibb Company Adult Non-Hodgkin Lymphoma Treatment Product Portfolios and Specifications
Table 146. Bristol Myers Squibb Company Adult Non-Hodgkin Lymphoma Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 147. Bristol Myers Squibb Company Main Business
Table 148. Bristol Myers Squibb Company Latest Developments
List of Figures
Figure 1. Picture of Adult Non-Hodgkin Lymphoma Treatment
Figure 2. Adult Non-Hodgkin Lymphoma Treatment Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Adult Non-Hodgkin Lymphoma Treatment Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Adult Non-Hodgkin Lymphoma Treatment Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Adult Non-Hodgkin Lymphoma Treatment Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of B Cell
Figure 10. Product Picture of T Cell
Figure 11. Product Picture of NK/T Cells
Figure 12. Global Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Type in 2022
Figure 13. Global Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2018-2023)
Figure 14. Adult Non-Hodgkin Lymphoma Treatment Consumed in Hospital
Figure 15. Global Adult Non-Hodgkin Lymphoma Treatment Market: Hospital (2018-2023) & (K Units)
Figure 16. Adult Non-Hodgkin Lymphoma Treatment Consumed in Clinic
Figure 17. Global Adult Non-Hodgkin Lymphoma Treatment Market: Clinic (2018-2023) & (K Units)
Figure 18. Global Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Application (2022)
Figure 19. Global Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Application in 2022
Figure 20. Adult Non-Hodgkin Lymphoma Treatment Sales Market by Company in 2022 (K Units)
Figure 21. Global Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Company in 2022
Figure 22. Adult Non-Hodgkin Lymphoma Treatment Revenue Market by Company in 2022 ($ Million)
Figure 23. Global Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Company in 2022
Figure 24. Global Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Geographic Region (2018-2023)
Figure 25. Global Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Geographic Region in 2022
Figure 26. Americas Adult Non-Hodgkin Lymphoma Treatment Sales 2018-2023 (K Units)
Figure 27. Americas Adult Non-Hodgkin Lymphoma Treatment Revenue 2018-2023 ($ Millions)
Figure 28. APAC Adult Non-Hodgkin Lymphoma Treatment Sales 2018-2023 (K Units)
Figure 29. APAC Adult Non-Hodgkin Lymphoma Treatment Revenue 2018-2023 ($ Millions)
Figure 30. Europe Adult Non-Hodgkin Lymphoma Treatment Sales 2018-2023 (K Units)
Figure 31. Europe Adult Non-Hodgkin Lymphoma Treatment Revenue 2018-2023 ($ Millions)
Figure 32. Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Sales 2018-2023 (K Units)
Figure 33. Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Revenue 2018-2023 ($ Millions)
Figure 34. Americas Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Country in 2022
Figure 35. Americas Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Country in 2022
Figure 36. Americas Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Type (2018-2023)
Figure 37. Americas Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Application (2018-2023)
Figure 38. United States Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 39. Canada Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 40. Mexico Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 41. Brazil Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 42. APAC Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Region in 2022
Figure 43. APAC Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Regions in 2022
Figure 44. APAC Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Type (2018-2023)
Figure 45. APAC Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Application (2018-2023)
Figure 46. China Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 47. Japan Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 48. South Korea Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 49. Southeast Asia Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 50. India Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 51. Australia Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 52. China Taiwan Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 53. Europe Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Country in 2022
Figure 54. Europe Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Country in 2022
Figure 55. Europe Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Type (2018-2023)
Figure 56. Europe Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Application (2018-2023)
Figure 57. Germany Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 58. France Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 59. UK Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 60. Italy Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 61. Russia Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 62. Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Country in 2022
Figure 63. Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Country in 2022
Figure 64. Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Type (2018-2023)
Figure 65. Middle East & Africa Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Application (2018-2023)
Figure 66. Egypt Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 67. South Africa Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 68. Israel Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 69. Turkey Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 70. GCC Country Adult Non-Hodgkin Lymphoma Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 71. Manufacturing Cost Structure Analysis of Adult Non-Hodgkin Lymphoma Treatment in 2022
Figure 72. Manufacturing Process Analysis of Adult Non-Hodgkin Lymphoma Treatment
Figure 73. Industry Chain Structure of Adult Non-Hodgkin Lymphoma Treatment
Figure 74. Channels of Distribution
Figure 75. Global Adult Non-Hodgkin Lymphoma Treatment Sales Market Forecast by Region (2024-2029)
Figure 76. Global Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share Forecast by Region (2024-2029)
Figure 77. Global Adult Non-Hodgkin Lymphoma Treatment Sales Market Share Forecast by Type (2024-2029)
Figure 78. Global Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share Forecast by Type (2024-2029)
Figure 79. Global Adult Non-Hodgkin Lymphoma Treatment Sales Market Share Forecast by Application (2024-2029)
Figure 80. Global Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share Forecast by Application (2024-2029)


★調査レポート[世界の成人非ホジキンリンパ腫治療市場予測 2023年-2029年] (コード：LP23DC02391)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の成人非ホジキンリンパ腫治療市場予測 2023年-2029年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の成人悪性神経膠腫治療市場予測 2023年-2029年
  • 世界の成人用軟性経鼻酸素カニューレ市場予測 2023年-2029年
  • 世界の成人用喉頭マスク市場予測 2023年-2029年
  • 世界の成人用喉頭マスク市場予測 2023年-2029年
  • 世界の筋骨格系腫瘍治療市場予測 2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆